Opportunities in viral vector manufacturing arise from rising demand for GMP-grade materials and increasing gene therapy ...

Rome, Italy – September 30 2025 – ReiThera Srl, the Italian leading Contract Development and Manufacturing Organization (CDMO) specialized in the development and GMP manufacturing of viral vectors for ...

This article examines key innovations driving scalable, high-yield purification of recombinant AAVs and how they’re helping ...

OXB has signed and closed an asset purchase transaction to acquire a custom-built cell and gene therapy viral vector manufacturing facility in North Carolina from RTP Operating. The acquisition ...

Receiving a platform technology designation from the FDA is a tremendous milestone for our development team and Krystal, both as recognition of the reproducibility and scalability of our HSV-1 gene ...

(MENAFN- GlobeNewsWire - Nasdaq) The viral vector gene therapy market size is calculated at USD 14.62 billion in 2025 and is expected to reach around USD 38.39 billion by 2034, growing at a CAGR of 11 ...

OXB acquires Resilience’s site in North Carolina, an FDA-approved, commercial-scale viral vector manufacturing facility In line with OXB’s previously announced strategy to add US GMP capacity across ...

OXB acquires Resilience’s site in North Carolina, an FDA-approved, commercial-scale viral vector manufacturing facility In line with OXB’s previously announced strategy to add US GMP capacity across ...

OXB expands US footprint with acquisition of commercial-scale viral vector facility in North Carolina - OXB acquires Resilience's site in North Carolina, an FDA-approved, commercial-scale viral vector ...